Navigation Links
Dr Nabil Dib Takes on Special Advisor Role to the Stemedica Board of Directors
Date:1/26/2009

Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).

San Diego, CA (PRWEB) January 26, 2009 -- Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).

"In looking for someone to serve as Special Advisor to the Board, we sought a medical leader who had practical experience in working with the FDA and the research community in advancing therapeutic stem cell solutions. We feel fortunate to have secured an Advisory Relationship with a true leader within the stem cell industry. Dr Nabil Dib has as much extensive research, regulatory and clinical application experience with adult stem therapy as anyone in the United States," said Nikolai Tankovich, MD, PhD, President & Chief Regulatory and Medical Officer of Stemedica.

In accepting the role of Special Advisor, Dr Dib said, "I'm honored to be associated with Stemedica Cell Technologies. As someone who strives to help build this industry, my research tells me that Stemedica stands out as a leader within our sector. Many stem cell research and manufacturing companies make significant progress in the laboratory, but what distinguishes Stemedica is the extent of their clinical research experience."

"With Dr. Dib we get an independent minded, diligent investigator who has the hands on proven experience in advancing stem cell research and technology from bench top to bed side with the highest possible concern for the safety of the patient and the efficacy of the application," said Maynard Howe, PhD, Vice Chairman and CEO for Stemedica.

About Stemedica Technologies, Inc.:
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, Calif.

For more information regarding Stemedica Cell Technologies or the Dr. Nabil Dib appointment, contact Dave McGuigan.

# # #

Read the full story at http://www.prweb.com/releases/2009/01/prweb1907844.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. AARP Disappointed in Senates Inability to Pass Health Care Reform
4. Creating Healing Environments: Healthcare Industrys Largest Sustainability Conference to be Held May 20-22 in Pittsburgh
5. Baxter Releases Ninth Annual Sustainability Report
6. Free will takes flight: how our brains respond to an approaching menace
7. New AHIP Report Takes a Ten Year Look at the Unintended Consequences of State Efforts to Change the Insurance Market
8. Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival
9. Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts
10. Small Town Doctor Takes on Giants in Consumer Healthcare
11. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs ... the Lincoln, Neb. area this year. , The first new location will open ... location will open at 84th and Northern Lights Drive this fall. And the third ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each year, ... most of us assume this type of accident will never happen to us, the ... the time to learn how to respond effectively or prevent these accidents from occurring ...
(Date:4/26/2017)... ... 26, 2017 , ... Jump Technologies, Inc., an innovative software ... completed a round of funding to accelerate its growth strategies. The $3.5 million ... is a growth equity firm focused on investments in healthcare and technology companies. ...
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology – Tooth ... to overall dental health, including complications with speech, eating, and overcompensation of mouth due ... replace lost teeth. As the number of tooth replacements increase, it is imperative to ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs ... of e-prescribing as measured in Part D Medicare data. The dataset, called PaPR ... either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data set ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: